<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623309</url>
  </required_header>
  <id_info>
    <org_study_id>HAPLOMUDELDERLY-IPC 2015-004</org_study_id>
    <nct_id>NCT02623309</nct_id>
  </id_info>
  <brief_title>Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic (Allo) hematopoietic stem cell transplantation (HSCT) is a recognized curative
      procedure for hematological malignancies. It is now well known that this property is related
      to the graft-versus-tumor (GVT) effect developed from the immunocompetent cells contained in
      or generating from the donor graft. For years, however, and despite this unique antitumoral
      activity, Allo-HSCT has been restricted to a limited number of patients due to two major
      limitations: the toxicity of the procedure and the absence of a donor for every single
      patients. More recently the stage has dramatically changed with respect to these two
      restraints. Over the last decade, many studies have established the feasibility of Allo-HSCT
      in older patients but the availability of MRD is even less frequent in elderlies, likely
      related to medical contraindication for graft donation or sibling deaths. UD are routinely
      used but associated with a high incidence of GVHD. As compared to younger populations,
      unrelated cord-blood HSCT is seldom performed in this population and numbers decrease with
      age due to the feared risk of supposed increased lethal infectious complications related to
      the effect of the delayed immune reconstitution in elderlies. Thus the need for alternative
      donors allowing for a safe and efficient transplantation is still unmet. In consequence,
      overall, despite the fact that Allo-HSCT feasibility has been established in the oldest
      patients, all these lacks contribute eventually to maintain a low rate of allo-HSCT performed
      in a population with the higher incidence of hematologic malignancies that usually present
      with the poorest prognosis.

      Thus it is critical developing innovative efficient therapeutic strategies answering this
      unmet-medical need. In this perspective, Haplo-HSCT could represent a part of the answer in
      this aged population. It offers the potential advantage to offer a rapid donor determination
      for virtually every single patient. In addition, our data suggest that in elderlies
      haplo-HSCT using T-repleted graft, RIC and PT-HDCy presents low NRM and retains an antitumor
      effect despite low GVHD incidences. They also suggest that haplo-HSCT may conduct to better
      outcome than URD-HSCT as an alternative to MRD-HSCT. It may also be associated with lower
      costs (no graft purchase and low post-transplant complications rate) and better QOL likely
      related to low cGVHD-rate. In addition the conduct of such trial at a time when the diffusion
      of the strategy in this population is just starting is really crucial before widespread
      uncontrolled dissemination.

      The investigators propose to address this question by prospectively comparing these 2
      strategies in elderly patients without MRD, in terms of efficacy, safety and including the
      prospective evaluation study of quality-of-life (QOL). They will conduct a national,
      multicenter, open-label, comparative, randomized phase III trial in patients with
      hematological malignancies justifying an allo-HSCT from an alternative donor when a MRD has
      not been identified.

      When MRD search is recognized to be a failure, patients will be included in the clinical
      trial after informed consent and randomized in the two strategies based on donor search:

        -  Reference group: Unrelated Donor group

        -  Investigational group: Haplo Donor Group

      Investigators will use a composite end-point embracing the three main causes of failure:
      death, relapse and severe cGVHD (as a surrogate endpoint for QOL). We will analyze the HSCT
      usual objectives as GHVD, NRM, relapse and survival. A specific study of patients' health
      related quality of life will also be conducted using the FACT-BMT questionnaire. In addition,
      the success of the two strategies in term of transplant completion (donor determination,
      transplant realization and time to do so) will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival with death, relapse or occurrence of severe cGVHD as event whatever occurs first</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment: time to reach 0.5 x 109/l ANC, 20 x 109/l platelets and full donor lymphoid chimerism</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic GVHD cumulative incidences</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality cumulative incidence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse incidence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probabilities of overall survival and progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of HRQL including patients who relapse</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of procedure costs from beginning of search until death or two-year follow-up</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>HAPLO graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conditioning regimen
Fludarabin : 30 mg/m2/day for 4 days: from D-5 à J-2.
Busulfan IV : 130 mg/m2/day for 2 days : drom D-4 to D-3. + 1 day of Thiotepa : 5mg/kg at D-6.
Prophylaxis regimen for GVHD
F CSA and MMF (starting day +5)
Additional immunosuppression: PT-HDCy (50 mg/kg/day) on days +3 and +4
Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg GCSF (Neupogen ®) during 4 to 5 days (D-4 to D-1): SC 10 µg/kg/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUD graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conditioning regimen
Fludarabin : 30 mg/m2/day for 5 days: from D-6 to D-2.
Busulfan IV : 130 mg/m2/day for 2 days: from D-4 to D-3.
Prophylaxis regimen for GVHD
CSA and MMF will be used from day -1 after UD
Additional immunosuppression: Rabbit ATG (2.5 mg/kg/day) on days -3 and -2
Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic (Allo) hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>HAPLO graft</arm_group_label>
    <arm_group_label>MUD graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged of 55 years or up to 70 years.

          -  Patients with hematological malignancy

          -  Patients without a matched related donor

          -  Patients eligible for an allogeneic HSCT from an alternative donor

          -  Able to comply with the protocol

          -  Written informed consent

          -  Affiliation to Social Security System

        Exclusion Criteria:

          -  Clinical or biological contraindication to allogeneic HSCT

          -  Other evolutive cancer

          -  Positive serology for HIV, hepatitis B or chronic active hepatitis C

          -  Pregnant or breast-feeding women.

          -  Emergency

          -  Patient considered socially or psychologically unable to comply with the treatment and
             the required medical follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Blaise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>+33 4 91 22 37 78</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihane PAKRADOUNI, PharmD,PhD</last_name>
    <phone>+33 4 91 22 37 78</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amandine Charbonnier, MD</last_name>
      <email>Charbonnier.Amandine@chuamiens.fr</email>
    </contact>
    <investigator>
      <last_name>Amandine Charbonnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Berceanu, MD</last_name>
      <email>aberceanu@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Ana Berceanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing/Clermont-ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Hermet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Hermet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques-Olivier Bay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude-Eric Bulabois, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claude-Eric Bulabois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Turlure, MD</last_name>
      <email>Pascal.turlure@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Turlure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique GENRE, MD</last_name>
      <phone>33491223778</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jihane PAKRADOUNI, PharmD, PhD</last_name>
      <phone>33491223778</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Didier BLAISE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice CEBALLOS, MD</last_name>
      <email>p-ceballos@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice CEBALLOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Fegueux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Chevallier, MD</last_name>
      <email>Patrice.chevallier@chunantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Suarez, MD</last_name>
      <email>felipe.suarez@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Felipe Suarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad Mohty, MD</last_name>
      <email>mohamad.mohty@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Mohamad Mohty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regis Peffault de latour, MD</last_name>
      <email>regis.peffaultdelatour@sls.aph</email>
    </contact>
    <investigator>
      <last_name>Regis Peffault de latour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Tabrizi, MD</last_name>
      <email>reza.tabrizi@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Reza Tabrizi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme CORNILLON, MD</last_name>
      <email>Jerome.cornillon@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme CORNILLON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Huynh, MD</last_name>
      <email>Huynh.Anne@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Huynh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

